Derek Archila Analyst Performance

Managing Director, Biotechnology Equity Research at Wells Fargo & Company

Derek Archila is a stock analyst at Wells Fargo & Company in the medical sector, covering 54 publicly traded companies. Over the past year, Derek Archila has issued 29 stock ratings, including buy and hold recommendations. While full access to Derek Archila's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Derek Archila's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 261 Last 8 Years
Buy Recommendations: 62.16% 161 Buy Ratings
Companies Covered: 54 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.4%	1 ratings
Buy	61.8%	160 ratings
Hold	37.8%	98 ratings
Sell	0.0%	0 ratings

Out of 259 total stock ratings issued by Derek Archila at Wells Fargo & Company, the majority (61.8%) have been Buy recommendations, followed by 37.8% Hold and 0.4% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
CBAY
May 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
SELB
Oct 2018
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	92.6% of companies on NASDAQ	50 companies
NYSE	7.4% of companies on NYSE	4 companies

Derek Archila, an analyst at Wells Fargo & Company, currently covers 54 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 54 companies	100.0%

Derek Archila of Wells Fargo & Company specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 28 companies	51.9%
PHARMACEUTICAL PREPARATIONS 16 companies	29.6%
MED - DRUGS 4 companies	7.4%
BIOTECHNOLOGY 3 companies	5.6%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	1.9%
MED PRODUCTS 1 company	1.9%
MED - GENERIC DRG 1 company	1.9%

About Derek Archila

Senior Equity Research Analyst specializing in small- and mid-cap biotechnology companies, with a primary focus on immunology & inflammation (I&I), targeted oncology, and rare diseases. I am a key contributor to the #4 ranked Wells Fargo SMID-cap biotech franchise, and was individually recognized as a “Runner-Up” in the Institutional Investor (Extel) poll for Biotechnology Small & Mid-Cap Equity Research in both 2023 and 2024, ranking among the top 5 analysts in 2024.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
KYTX Kyverna Therapeutics	10/8/2025	Boost Price Target	$5.41	$27.00	Overweight
CCCC C4 Therapeutics	9/23/2025	Boost Price Target	$2.61	$10.00	Overweight
ATYR aTyr Pharma	9/15/2025	Reiterated Rating	$1.05		Equal Weight
SLNO Soleno Therapeutics	8/20/2025	Initiated Coverage	$66.81	$123.00	Overweight
CLDX Celldex Therapeutics	8/20/2025	Lower Price Target	$21.24	$38.00	Overweight
STRO Sutro Biopharma	8/12/2025	Lower Price Target	$0.77	$3.00	Equal Weight
ASND Ascendis Pharma A/S	8/8/2025	Reiterated Rating	$190.35	$295.00	Overweight
ZNTL Zentalis Pharmaceuticals	8/7/2025	Lower Price Target	$1.43	$5.00	Equal Weight
VRDN Viridian Therapeutics	8/7/2025	Lower Price Target	$16.71	$26.00	Equal Weight
ARVN Arvinas	8/7/2025	Lower Price Target	$6.14	$16.00	Overweight
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
INCY Incyte	8/6/2025	Upgrade	$77.72	$89.00	Overweight
ARGX argenex	7/31/2025	Boost Price Target	$670.33	$756.00	Overweight
INCY Incyte	7/30/2025	Boost Price Target	$77.88	$67.00	Equal Weight
ALMS Alumis	7/25/2025	Initiated Coverage	$4.05	$17.00	Overweight
RYTM Rhythm Pharmaceuticals	7/10/2025	Boost Price Target	$89.53	$129.00	Overweight
KYMR Kymera Therapeutics	6/26/2025	Lower Price Target	$44.98	$53.00	Overweight
ATYR aTyr Pharma	6/20/2025	Boost Price Target	$5.17	$25.00	Overweight
BPMC Blueprint Medicines	6/17/2025	Downgrade	$128.16	$129.00	Hold
APLS Apellis Pharmaceuticals	6/2/2025	Boost Price Target	$19.21	$29.00	Equal Weight
APLS Apellis Pharmaceuticals	5/8/2025	Lower Price Target	$17.90	$26.00	Equal Weight
ARVN Arvinas	5/2/2025	Lower Price Target	$7.78	$19.00	Overweight
INCY Incyte	4/30/2025	Boost Price Target	$61.16	$59.00	Equal Weight
NRIX Nurix Therapeutics	4/9/2025	Lower Price Target	$9.86	$25.00	Overweight
RYTM Rhythm Pharmaceuticals	4/7/2025	Boost Price Target	$54.94	$91.00	Overweight
ARVN Arvinas	3/12/2025	Set Price Target	$8.51	$26.00	Overweight
ARGX argenex	2/28/2025	Boost Price Target	$619.04	$741.00	Overweight
EXEL Exelixis	2/24/2025	Downgrade	$36.85	$36.00	Equal Weight
ANAB AnaptysBio	2/13/2025	Boost Price Target	$19.29	$51.00	Overweight
ZNTL Zentalis Pharmaceuticals	1/30/2025	Lower Price Target	$1.66	$6.00	Equal Weight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.